UK Retailers Take Divergent Paths With CBD Enforcement On Horizon
Predicted to be worth at least half a billion dollars by the end of the year, the UK's CBD market shows no sign of slowing down. However, regulatory and consumer confusion is distributing the benefits of this growth unevenly, and holding back mass market retailers from leaning in fully, according to a HBW Insight analysis.
You may also be interested in...
UK CBD supplier TTS Pharma believes its strategy of establishing partnerhips with local food law enforcement agencies as part of the "assured advice" scheme will unlock the country's cautious mass market. However, without proactive enforcement, the company worries that the UK food authority's legislative efforts to remove sub-standard CBD products from the market, as well as TTS' own efforts to become compliant, will be in vain.
In itself, the proposed US Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2020 may be of little consequence. But the FDA’s October comments on the bill were revealing, CV Sciences’ Duffy MacKay says.
New York proposal for packaging and testing hemp-derived cannabinoids could be ‘de facto’ standard for other stat, say attorneys tracking the patchwork of state laws. The proposal sets per-product concentration limits and includes licensing fees for processors and retailers.